IDEAYA Biosciences (IDYA)
29.33
+1.04 (3.68%)
Upcoming Events
Latest Headlines
Form 3 IDEAYA Biosciences, Inc. For: Mar 18 Filed by: Ross Theodora
June 5, 2026 2:06 PM - SEC Filing
Ideaya Biosciences (IDYA) Reiterated at Overweight by Cantor Fitzgerald
June 3, 2026 6:48 AM - StreetInsider
Form 8-K IDEAYA Biosciences, Inc. For: Jun 03
June 3, 2026 6:05 AM - SEC Filing
IDEAYA Biosciences partners with Roche for pancreatic cancer study
June 3, 2026 6:00 AM - StreetInsider
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
June 3, 2026 6:00 AM - PR NewsWire
Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens
June 2, 2026 4:30 AM - StreetInsider
Form 8-K IDEAYA Biosciences, Inc. For: Jun 01
June 1, 2026 4:07 PM - SEC Filing
IDEAYA reports positive phase 2/3 trial results for uveal melanoma drug
June 1, 2026 11:00 AM - StreetInsider
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
June 1, 2026 11:00 AM - PR NewsWire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 29, 2026 6:00 AM - PR NewsWire
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
May 26, 2026 6:00 AM - PR NewsWire
Ideaya Biosciences (IDYA) Reiterated at Overweight by Cantor Fitzgerald
May 22, 2026 7:30 AM - StreetInsider
Form SCHEDULE 13G/A IDEAYA Biosciences, Inc. Filed by: JANUS HENDERSON GROUP PLC
May 15, 2026 12:38 PM - SEC Filing
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
May 14, 2026 9:15 AM - StreetInsider
Ideaya Biosciences (IDYA) PT Lowered to $50 at Mizuho
May 7, 2026 6:50 AM - StreetInsider
Form 8-K IDEAYA Biosciences, Inc. For: May 05
May 5, 2026 5:22 PM - SEC Filing
Form 424B5 IDEAYA Biosciences, Inc.
May 5, 2026 5:20 PM - SEC Filing
IDEAYA Biosciences (IDYA) files mixed shelf
May 5, 2026 4:29 PM - StreetInsider
Form S-3ASR IDEAYA Biosciences, Inc.
May 5, 2026 4:28 PM - SEC Filing
Form 10-Q IDEAYA Biosciences, Inc. For: Mar 31
May 5, 2026 4:06 PM - SEC Filing
IDEAYA Biosciences (IDYA) Misses Q1 EPS by 12c
May 5, 2026 6:19 AM - StreetInsider
Form 8-K IDEAYA Biosciences, Inc. For: May 05
May 5, 2026 6:08 AM - SEC Filing
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
May 5, 2026 6:00 AM - PR NewsWire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 1, 2026 6:00 AM - PR NewsWire
Form DEFA14A IDEAYA Biosciences, Inc.
April 30, 2026 4:09 PM - SEC Filing
IDEAYA begins FDA application for uveal melanoma drug under fast-track program
April 30, 2026 6:01 AM - StreetInsider
IDEAYA Biosciences to Initiate New Drug Application Submission from the Darovasertib OptimUM-02 Trial under the Oncology Center of Excellence Real-time Oncology Review (RTOR) Program
April 30, 2026 6:00 AM - PR NewsWire
Form DEF 14A IDEAYA Biosciences, Inc. For: Jun 16
April 29, 2026 4:07 PM - SEC Filing
Form ARS IDEAYA Biosciences, Inc. For: Dec 31
April 29, 2026 4:05 PM - SEC Filing
IDEAYA to present Phase 2/3 uveal melanoma trial data at ASCO 2026
April 21, 2026 10:15 AM - StreetInsider
IDEAYA Biosciences Announces Late-Breaking Abstract Oral Presentation at ASCO 2026 to Provide Complete Data from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizoti
April 21, 2026 10:15 AM - PR NewsWire
Ideaya Biosciences (IDYA) PT Raised to $54 at Guggenheim
April 14, 2026 7:04 AM - StreetInsider
Ideaya Biosciences (IDYA) PT Raised to $48 at Wells Fargo
April 14, 2026 7:01 AM - StreetInsider
Ideaya Biosciences (IDYA) PT Raised to $53 at RBC Capital
April 14, 2026 6:39 AM - StreetInsider
Ideaya Biosciences (IDYA) PT Raised to $52 at Mizuho, 'we recommend being opportunistic'
April 13, 2026 3:08 PM - StreetInsider
Ideaya Biosciences (IDYA) PT Raised to $40 at Oppenheimer
April 13, 2026 3:04 PM - StreetInsider
Ideaya Biosciences (IDYA) PT Raised to $65 at Truist Securities
April 13, 2026 2:05 PM - StreetInsider
Ideaya Biosciences (IDYA) PT Raised to $35 at Goldman Sachs
April 13, 2026 1:29 PM - StreetInsider
Ideaya Biosciences (IDYA) PT Raised to $58 at Wedbush
April 13, 2026 10:14 AM - StreetInsider
Form 8-K IDEAYA Biosciences, Inc. For: Apr 13
April 13, 2026 6:05 AM - SEC Filing
IDEAYA and Servier report positive phase 2/3 trial results for uveal melanoma
April 13, 2026 6:00 AM - StreetInsider
IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Meta
April 13, 2026 6:00 AM - PR NewsWire
IDEAYA to report uveal melanoma trial results April 13
April 10, 2026 4:05 PM - StreetInsider
IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026
April 10, 2026 4:05 PM - PR NewsWire
Form 8-K IDEAYA Biosciences, Inc. For: Apr 08
April 9, 2026 6:06 AM - SEC Filing
IDEAYA Biosciences begins phase 1 trial of cancer drug IDE574
April 6, 2026 6:00 AM - StreetInsider
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, C
April 6, 2026 6:00 AM - PR NewsWire
IDEAYA Biosciences begins combination study for cancer drugs
March 30, 2026 6:00 AM - StreetInsider
IDEAYA Biosciences Announces First-Patient-In for Phase 1 Combination Study of IDE849, DLL3 TOP1 ADC, and IDE161, PARG Inhibitor, in DLL3 Upregulated Solid Tumor Indications, including SCLC, NETs, NEC
March 30, 2026 6:00 AM - PR NewsWire
Form SCHEDULE 13G/A IDEAYA Biosciences, Inc. Filed by: VANGUARD GROUP INC
March 27, 2026 9:56 AM - SEC Filing
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 27, 2026 6:00 AM - PR NewsWire
IDEAYA Biosciences (IDYA) April 22.50 ad May 30 puts active
March 23, 2026 3:30 PM - StreetInsider
RBC Capital on Ideaya Biosciences (IDYA): 'We remain positive on the upcoming data readout'
March 23, 2026 2:21 PM - StreetInsider
Jefferies on Ideaya Biosciences (IDYA): 'simulation suggests ~90%+ chance for stat sig mPFS w/ 80% POS for mPFS >7'
March 23, 2026 12:01 PM - StreetInsider
Mizuho on Ideaya Biosciences (IDYA): 'we recommend being opportunistic on weakness'
March 23, 2026 9:42 AM - StreetInsider
Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens Ahead of mPFS Data
March 23, 2026 4:56 AM - StreetInsider
IDEAYA Biosciences delays database lock for darovasertib trial to april
March 22, 2026 10:00 AM - StreetInsider
IDEAYA Biosciences Upcoming Investor Relations Events and Updated Darovasertib Topline Results Guidance from Phase 2/3 OptimUM-02 Trial
March 22, 2026 10:00 AM - PR NewsWire
IDEAYA Biosciences Announces Upcoming Presentations at AACR 2026 Highlighting Multiple Clinical Stage Pipeline Programs
March 18, 2026 6:00 AM - PR NewsWire
Cantor Fitzgerald Reiterates Overweight Rating on Ideaya Biosciences (IDYA)
March 16, 2026 7:24 AM - StreetInsider
Full Article List
